Integrative Research Grants (Gateway for Cancer Research)

Integrative Research Grants (Gateway for Cancer Research) is sponsored by Gateway for Cancer Research. Gateway for Cancer Research funds integrative oncology research that combines conventional therapies with evidence-based complementary therapies to manage symptoms, reduce side effects, and improve quality of life for cancer patients.

For Researchers - Gateway For Cancer Research Accelerating practice-changing discoveries in cancer care Learn more about the spectrum of funding programs from Gateway Explore early phase clinical trials currently funded by Gateway Access grant applications, review submissions and clinical trial progress A PATIENT-CENTRIC FUNDING APPROACH Gateway for Cancer Research is one of the only nonprofits that exclusively funds Phase I and Phase II cancer clinical trials for patients of all ages, across all cancer types.

At the vanguard of discovery science, early-phase research is the first step in developing new treatments and therapies, and is often underfunded by traditional sources. We invest in innovative early-stage research that has the potential to shift the paradigm for standard of care and make a meaningful difference in the lives of cancer patients.

Gateway is proud to partner with dedicated clinician-scientists at leading cancer centers and research institutions around the world who share our commitment to patients and to ending cancer as we know it. Patient-Centered Research Gateway is focused on empowering patients and their caregivers on their cancer journey.

Patient advocates sit at every level of the organization, including the Research and Grants Committee that reviews all grant proposals. At Gateway, it is always and only about the patient. Clinician-scientists are incentivized to put patients at the center of their work, and patient impact is an important part of the peer review grant scoring process.

All Gateway grantees are asked to actively engage patients – before, during and after their participation in a Gateway-funded trial – to share their experiences with Gateway. This helps ensure Gateway’s understanding of the patient experience and inform future research funding priorities.

Practice-Changing Innovation Early-phase cancer clinical trials are the first step in evaluating new cancer drugs, treatments and therapies that will change the face of cancer care. Gateway-funded trials bring potentially life-saving breakthroughs to the patient’s bedside at renowned research institutions around the world. They yield real, tangible results for cancer patients.

Gateway funds integrative oncology research that promotes treatment while supporting quality of life. Integrative medicine combines conventional therapies such as surgery, chemotherapy and radiation with scientific evidence-based therapies to mitigate side effects and improve tolerability while treating the underlying disease At Gateway, we are committed to empowering patients to triumph over their disease.

To ensure patient voices are amplified in funded research, we require funded investigators to place patients at the center of their work. All Gateway-funded trials should: Gather feedback from patients and their advocates: Enables patient perspective to be heard during the clinical trial and in subsequent projects.

Monitor measures of patient quality of life and sense of hope: Ensures patients physical and mental well-being are prioritized throughout their cancer journey. Track the burden of treatment on patients and caregivers: Understand and reduce any obstacles that may arise during participation in the clinical trial. Gateway funded researcher Gateway is doing something that is really unique.

They’re allowing so many patients to be able to participate in clinical trials that otherwise wouldn’t exist without this funding. And it is changing patients’ lives. Chief of Breast Oncology at Dana-Farber Cancer Institute Gateway only invests in Phase I and Phase II human clinical trials where true innovation and transformational discoveries happen.

Trial Type: Breast Cancer HERizon-Breast: A curative-intent ctDNA-guided adaptive study of sequential anti-HER2 therapies and CNS prophylaxis to induce long-term remission in patients with metastatic HER2+ breast cancer Memorial Sloan Kettering Cancer Center Enasidenib for Patients with Clonal Cytopenias of Undetermined Significance Washington University in St.

Louis Browse frequently asked questions about research programs offered by Gateway It costs just $34. 00 per patient per day in a Gateway-funded cancer clinical trial. Help us fund another day of research, another week or more.

You can even mark your gift with a special date, such as an anniversary, birthday, wedding, bar/bat mitzvah or graduation.